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Abstract
The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor that mediates many of the biological and
toxicological actions of structurally diverse chemicals. In this study, we examined the ability of a series of ginsenosides
extracted from ginseng, a traditional Chinese medicine, to bind to and activate/inhibit the AHR and AHR signal transduction.
Utilizing a combination of ligand and DNA binding assays, molecular docking and reporter gene analysis, we demonstrated
the ability of selected ginsenosides to directly bind to and activate the guinea pig cytosolic AHR, and to stimulate/inhibit
AHR-dependent luciferase gene expression in a recombinant guinea pig cell line. Comparative studies revealed significant
species differences in the ability of ginsenosides to stimulate AHR-dependent gene expression in guinea pig, rat, mouse and
human cell lines. Not only did selected ginsenosides preferentially activate the AHR from one species and not others, mouse
cell line was also significantly less responsive to these chemicals than rat and guinea pig cell lines, but the endogenous gene
CYP1A1 could still be inducted in mouse cell line. Overall, the ability of these compounds to stimulate AHR signal
transduction demonstrated that these ginsenosides are a new class of naturally occurring AHR agonists.
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Introduction
The aryl hydrocarbon receptor (AHR) is a basic helix–loop–
helix PAS-containing transcription factor, which activates gene
expression in a ligand-dependent manner [1]. Exposure to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD, dioxin), the prototypical and
most potent AHR ligand, results in a wide variety of species- and
tissue-specific toxic and biological responses, the majority of which
are AHR dependent [2,3]. Following ligand binding, the cytosolic
AHR protein complex, which contains two molecules of hsp90,
the X-associated protein 2, and the co-chaperone p23, translocates
into the nucleus [4,5], the ligand-bound AHR is released upon its
dimerization with the ARNT (Ah receptor nuclear translocator)
protein, and the AHR is converted into its high-affinity DNA
binding form [1,6,7]. Binding of the heteromeric ligand:AH-
R:Arnt complex to its specific DNA recognition site, the dioxin
response element (DRE), upstream of cytochrome P4501A1
(CYP1A1) and other AHR-responsive genes, stimulates their
transcription [1,3].
The best characterized high-affinity ligands for the AHR
include a variety of synthetic halogenated aromatic hydrocarbons
(HAHs), such as the polychlorinated dibenzo-p-dioxin, dibenzo-
furans, and biphenyls, as well as numerous polycyclic aromatic
hydrocarbons (PAHs), such as benzo(a)pyrene, 3-methylcholan-
threne, and others [2,8]. More recently, a relatively large number
of natural and synthetic AHR ligands (agonists and antagonists)
whose structures and physicochemical characteristics are dramat-
ically different from that of the prototypical HAH and PAH have
been identified and characterized [9–11]. While the relative
potencies of these diverse ligands in intact cells and animals are
typically much lower than that of the HAHs and PAHs,
predominantly due to differences in their affinity, intrinsic efficacy,
and metabolic stability [8,10–12], these results demonstrate that
the AHR has an extremely promiscuous ligand binding pocket,
and raised questions as to the actual spectrum of chemicals that
can bind to and activate the AHR and AHR signaling pathway.
Accordingly, we have carried out bioassay screening analysis of a
wide variety of natural compounds and extracts with the goal to
identify and characterize novel AHR ligands, and extend our
understanding of the AHR ligand structural diversity.
Ginseng has been used as traditional medicine in China, Korea,
Japan and other Asian countries for thousands of years. While
there are seven major species of ginseng in East Asia, Central Asia,
and North America, most studies have focused on constituents
from three common species: Panax ginseng (Asian ginseng), Panax
quinquefolius (American ginseng), and Panax japonicus (Japanese
ginseng). The majority of the diverse pharmacological and
biochemical actions of ginseng appeared to be attributed to
ginseng saponins (ginsenosides), and more than 60 different
ginsenosides have been isolated from members of the Panax
genus [13]. While there is was antagonistic action by the ginseng
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saponin components resulting in inhibition of cellular prolifera-
tion, ginsenosides can also stimulate cell growth [14].
The diversity of AHR ligand structure coupled with the ability
of numerous natural products to bind to the AHR [8–11], and the
recent identification of two common clinically used ginsenosides
(Rg1 and Rb1) that can increase CYP1A1 mRNA levels in human
cells in culture [15], suggests that these compounds may be AHR
ligands. However, while induction of human CYP1A1 gene
expression is known to be mediated by the AHR, several studies
have also demonstrated induction by the retinoic acid receptor
and other signaling mechanisms [3,16–18]. Additionally, since the
study of Wang et al. (2008) did not determine whether these
compounds directly stimulated induction of CYP1A1, or whether
the response was secondary (i.e. due to a ginsenoside metabolite or
activation of an alternative pathway), the mechanism(s) responsible
for ginsenoside-dependent induction of CYP1A1 still remains an
open question [15]. Accordingly, here we described the results of
studies examining the ability of a series of ginsenosides to stimulate
AHR-dependent gene expression and confirmed their identity as
AHR ligands.
Materials and Methods
Chemicals
The specific ginsenosides used in this study (Rb1, Rb2, Rb3, Rc,
Rd, Re, Rg1, Rg2, Rh1, Rh2, PPD, PPT, F11, and a total
ginsenosides (TG) mixture (Figure 1 & Table 1), were kindly
provided by Dr. Huijun Yin (Chinese Academy of Medical
Sciences, Beijing, China) and were of greater than 98% purity.
TCDD, 2,3,7,8-tetrachlorodibenzofuran (TCDF), and [3H]-
TCDD (10 Ci/mmol) were obtained from S. Safe (Texas A&M
University, College Station, TX USA). [32P]-ATP (6000 Ci/
mmol) was purchased from Amersham (Arlington Heights, IL
USA) and DMSO from Sigma-Aldrich. Cell culture media was
purchased from Gibco (Invitrogen), fetal calf serum was purchased
from Lonza (BioWhittaker) and G418 was from Gemini Bio-
Products (Woodland, CA USA). Water was purified using a Milli-
Q water purification system (Millipore). All other chemicals were
of analytic purity.
Cell Culture, Chemical Treatment, and Ahr-Dependent
Luciferase Reporter Gene Expression
Recombinant guinea pig intestinal adenocarcinoma
(G16L1.1c8) cells and rat (H4L1.1c4), mouse (H1L1.1c2) and
human (HG2L6.1c3) hepatoma cells were grown and maintained
as described [19]. G16L1.1c8, H4L1.1c4 and H1L1.1c2 cells
contain the stably integrated DRE-driven firefly luciferase reporter
plasmid pGudLuc1.1, HG2L6.1c3 cells contain pGudLuc6.1 [20]
and the transcriptional activation of those plasmids occurs in a
time-, ligand-, dose-, and AHR-dependent manner [19,21]. Cells
were plated into white, clear-bottomed 96-well tissue culture dishes
at 75,000 cells per well and allowed to attach for 24 h. Cells were
incubated with carrier solvent DMSO (1% final solvent concen-
tration), TCDD (1 nM), or the indicated ginsenoside (for
measurement of agonist activity), or 1 nM TCDD plus the
indicated ginsenoside (for measurement of antagonist activity) for
4 h at 37uC. For luciferase measurement, sample wells were
washed twice with phosphate-buffered saline, followed by the
addition of cell lysis buffer (Promega) and shaking of the plates for
20 min at room temperature to allow cell lysis. Measurement of
luciferase activity in each well was carried out using a microplate
luminometer (TECAN Infinite 200 Multi Reader)with automatic
injection of Promega stabilized luciferase reagent. Luciferase
activity in each well was expressed relative to that induced by
1 nM TCDD.
Homology Modeling
The LBD structure of the guinea pig AHR (gpAHR) was
predicted by homology modeling, using the same procedure
previously adopted for the mouse, rat and human AHRs (mAHR,
rtAHR, huAHR) [22]. In brief, three X-ray structures of HIF-2a´
co-crystallized with the THS ligands (3F1O, 3H7W and 3H82)
were used as templates. MODELLER version 9v7 [23–25] was
used to perform homology modeling, by activating the option to
transfer all the THS structures from the templates to the final
homology model. One hundred models were obtained by random
generation of the starting structure and the DOPE score [26] was
used to rank the models. Four conformational clusters were
identified in this set of models, and a representative conformation
for each cluster (the one with the best DOPE score) was selected
for the ensemble docking calculations.Figure 1. Backbone structures of ginsenosides. Each type of
ginsenosides differ at two side chains OR1 and OR2 attached to the
common steroid ring.
doi:10.1371/journal.pone.0066258.g001
Table 1. Structures of ginsenosides examined in this study.
Category Name Side chain
R1 R2
PPD type Rb1 -Glc2-Glc -Glc6-Glc
Rb2 -Glc2-Glc -Glc6-Ara(p)
Rb3 -Glc2-Glc -Glc6-Xyl
Rc -Glc2-Glc -Glc6-Ara(f)
Rd -Glc2-Glc -Glc
Rh2 -Glc -H
PPD -H -H
PPT type Re -Glc2-Rha -Glc
Rg1 -Glc -Glc
Rg2 -Glc2-Rha -H
Rh1 -Glc -H
PPT -H -H
Special type F11
TG
Abbreviations for carbohydrates are as follows: Glc, glucopyranoside; Ara,
arabinopyranoside; Rha, rhamnopyranoside; Xyl, xylopyranoside; TG, total
ginsenosides (mixed compounds). Superscripts indicated the carbon in the
glucose ring that linked the two carbohydrates.
doi:10.1371/journal.pone.0066258.t001
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Ligand Conformational Analysis
Conformational search of the ginsenoside ligands (PPD and
PPT) in the free state was performed using the MacroModel 9v9
[27] program included in Maestro 9v3 [28] with the following
parameters: OPLS-2005 force field [29], implicit (Generalized
Born/Solvent Accessible, GB/SA) water solvation [30], automatic
set up of the conformational degrees of freedom, and Monte Carlo
Multiple Minimum (MC/MM) random search algorithm. The five
most stable conformational minima for each ligand were selected
for docking calculations.
Molecular Docking
The ensemble docking approach previously proposed for ligand
docking to the AHR homology models [22] was used. Accord-
ingly, the four representative conformations selected in the
ensemble of homology models of the gpAHR were used for
docking. To account for the ginsenosides’ conformational
variability, the five conformations selected for PPD and PPT
were utilized for docking analysis. Flexible ligand docking of the
two ginsenosides and the TCDD was carried out using the Glide
5.8 program [31] with the Glide extra-precision (XP) protocol
[32]. The binding box was centered in the averaged Cartesian
coordinates of the template THS ligands centroids, with 25 A˚ sides
length. All the other parameters were of the default ones. The final
best scoring pose for each ligand was selected by using the Glide
XP scoring function [32]. Docking calculations with the same
ligands were performed, for comparative purposes, in the modeled
mAHR, rtAHR and huAHR LBDs [22] using the same
computational protocol.
Refinement of The Docking Poses
Energy minimization of all the obtained AHR/ligand complex-
es was carried out with the MacroModel 9.9 program [27,28]. The
OPLS-2005 force field [29], the implicit GB/SA water solvation
model [30] and the TNCG minimization algorithm were
employed in this analysis. Different degrees of system flexibility
were imposed: the ligands and the side chains of the residue shell
within 5 A˚ from the ligands were defined as free to move; the
backbones of the residue shell within 5 A˚ from the ligands were
constrained with a force constant of 200 kJ*mol21*A˚22, the
residues within 5–7 A˚ from the ligands were constrained with a
force constant of 500 kJ*mol21*A˚22, and all the remaining
residues were frozen.
Rt-Pcr Analysis of Endogenous Gene Cyp1a1 Induction
Forward and reverse RT-PCR primers were synthesized and
contained the following sequences: mCYP1A1 FP, 59-
CCTCATGTACCTGGTAACCA-39; and mCYP1A1 RP, 59-
AAGGATGAATGCCGGAAGGT-39, and a highly conserved
region of a constitutively expressed housekeeping gene, GAPDH
FP, 59-TGCACCACCAACTGCTTAG-39; and GAPDH RP, 59-
GATGCAGGGATGATGTTC-39 [33]. Confluent mouse hepa-
toma cells (hepa1c1c7) were treated with 1% carrier solvent
(DMSO), 1 nM TCDD, or 10 mM ginsenoside for 4 h, respec-
tively, prior to mRNA isolation using TRIzol (Invitrogen). Single
stranded cDNA was synthesized using RevertAid First Strand
cDNA Synthesis Kit (Fermentas) according to the manufacturer’s
instructions and used for PCR amplification. PCR reactions were
conducted in final volume of 20 mL and performed on equal
amounts of reverse-transcribed products, using SYBR Green
Master mix and Rox reference dye, according to the manufac-
turer’s instructions (Promega). All PCR reactions were performed
and analyzed in a Stratagene real-time PCR machine (MX3005P,
USA). The specificity of amplification was confirmed by melting
curves and by gel electrophoresis.
Preparation of Cytosol Extracts
Male Hartley guinea pigs (250–300 g), obtained from Charles
River Breeding Laboratories (Wilmington, DE), were exposed to
12 h of light and 12 h of dark daily and were allowed free access to
food and water. Hepatic cytosol was prepared in HEDG buffer
(25 mM Hepes (pH 7.5), 1 mM EDTA, 1 mM DTT, and 10%
(v/v) glycerol) as previously described [21]. The resulting cytosolic
extract was stored frozen at 280uC until use. Protein concentra-
tions were determined by dye binding using bovine serum albumin
as the standard. All procedures and experiments with animals and
animal-derived materials were reviewed and approved by the
University of California Davis Institutional Animal Care and Use
Committee (approval ID 08-13392).
Gel Retardation Assay
Complementary synthetic oligonucleotides containing the
DRE3 AHR DNA binding site 59-GATCTGGCTCTTCT-
CACGCAACTCCG-39 and 59-GATCCGGAGTTGCGTGA-
GAA GAGCCA-39 were prepared, annealed, and end-labeled
with [32P]ATP as described [21]. Guinea pig hepatic cytosol
(8 mg/ml in HEDG) was incubated for 2 h in a room temperature
water bath with DMSO (2%), TCDD (20 nM)), or the indicated
ginsenoside (200 mM). An aliquot of the reaction was mixed with
poly[dINdC] and [32P]-DRE (100,000 cpm), and AHR:-
DRE:[32P]DRE complexes were resolved by gel retardation
analysis, visualized by autoradiography and quantified by
phosphorimager analysis (Molecular Dynamics, Sunnyvale, CA
USA) of the dried gels [21].
Ligand Binding Analysis
Aliquots of guinea pig hepatic cytosol (2 mg protein/ml) were
incubated with 2 nM [3H]TCDD in the presence of DMSO (1%),
TCDF (200 nM), the indicated solvent or ginsenoside (200 mM)
for 2 h in a room temperature water bath. [3H]TCDD binding in
aliquots of the incubation (200 ml) was determined by HAP
binding as previously described [21]. The total amount of
[3H]TCDD specific binding was obtained by subtracting the
nonspecific binding ([3H]TCDD + TCDF) from the total binding
([3H]TCDD), and the ability of ginsenosides to bind to the AHR
was indicated by their ability to competitively reduce [3H]TCDD
specific binding.
Results
Agonist And Antagonist Activity of Ginsenosides in
Guinea Pig G16l1.1c8 Cells
We first examined the AHR agonist activity of a series of
ginsenosides by testing their ability to stimulate AHR-dependent
reporter gene expression in recombinant guinea pig intestinal
adenocarcinoma cells (G16L1.1c8) that contain the stably
transfected DRE-luciferase reporter plasmid pGudLuc1.1. Con-
centration-dependent induction of luciferase by ginsenosides at 4 h
was observed in this cell line, and some ginsenosides were found to
stimulate AHR-dependent reporter gene expression at concentra-
tions of 1 mM (Rh2, PPT) and 10 mM (Rb3, Rc, Rh1, Rh2, F11,
TG) (Figure 2). Both PPD and PPT reduced TCDD-dependent
luciferase induction in the same cell line, and luciferase gene
expression induced by TCDD was reduced by Rh2, PPD, PPT
and F11 in guinea pig cell line.
Ginsenosides Are Novel AHR Ligands
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Stimulation of AHR transformation and DNA binding by
TCDD and ginsenosides in vitro
The reporter gene expression results demonstrated the ability of
selected ginsengosides to activate AHR-dependent gene expres-
sion, but they did not address whether this induction was direct
(i.e. the ginsenoside binds to and activates the AHR) or indirect (a
metabolite of the ginsenoside binds to the AHR and/or it activates
the AHR by a mechanism that does not involve direct binding to
the AHR). To address this, we examined the ability of ginsenosides
to directly stimulate transformation and DNA binding of guinea
pig cytosolic AHR in vitro using gel retardation analysis. The results
of these analyses (Figure 3) revealed that the ginsenosides Rc, Rh1,
F11 and TG could stimulate AHR:DRE complex formation to a
level greater than 40% of that maximally induced by TCDD, with
Rc producing maximal AHR:DRE complex formation (9966 %
of that of TCDD). While the DNA binding analysis results
indicated that at least four ginsenosides could stimulate AHR
transformation and DNA binding in vitro, we did not examine
whether these compounds were actually AHR ligands.
Competitive Binding of Ginsenosides to The Guinea Pig
Hepatic Cytosolic Ahr
To determine whether these ginsenosides were ligands for the
AHR, we evaluated their ability to compete with [3H]TCDD for
binding to the AHR. The results of these studies revealed that
many ginsenosides (Table 2), including Rc, Rd, Re, Rg2, Rh1,
Rh2, PPD, PPT, F11 and TG, could competitively bind to the
AHR, displacing between 20 and 80% of [3H]TCDD specific
Figure 2. Induction of luciferase activity by ginsenosides in
AHR-responsive recombinant guinea pig G16L1.1c8 cells. (A)
G16L1.1c8 cells were treated with 1 mM or 10 mM ginsenosides for 4 h.
(B) G16L1.1c8 cells were treated with 1 mM/10 mM ginsenosides + 1 nM
TCDD for 4 h and luciferase activity was determined as described in
Materials and Methods section. Values were expressed in the figure as
the percentage of maximal TCDD induction and represented the mean
6 SD of triplicate determinations. The asterisk indicated that the values
of induction or inhibition was significantly increased compared to
DMSO-treated sample at p,0.05 (*).
doi:10.1371/journal.pone.0066258.g002
Figure 3. Stimulation of AHR transformation and DNA binding
by TCDD and ginsenosides in vitro. Guinea pig hepatic cytosol
(8 mg protein/mL) was incubated with DMSO (20 mL/mL, final
concentration), 20 nM TCDD, or 200 mM of the indicated ginsenosides
for 2 h at 20uC. Protein-DNA complexes were resolved by gel
retardation analysis. Protein–DNA complexes were resolved by gel
retardation analysis (a) and the amount of induced protein–DNA
complex formation determined by phosphorimager analysis (b). The
arrow indicated the position of the AHR:DRE complex. Values were
expressed in the figure as the percentage of maximal combination by
TCDD and represented the mean 6 SD of triplicate determinations. The
asterisk indicated that the combination was significantly induced
compared to DMSO-treated sample at p,0.05 (*). Induced complex
formation at all concentrations of TCDD $10211 M and of ginsenosides
$1027 M were significantly greater than the DMSO-treated sample at
p,0.01 as determined by Student’s t-test.
doi:10.1371/journal.pone.0066258.g003
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binding. Similar to its relatively high efficacy to stimulate AHR
DNA binding, Rc competitively displaced ,90% of [3H]TCDD
specific binding. While competitive binding by Rc, Rh1, Rh2, F11
and TG were consistent with their agonist activities in the gene
expression studies, comparison of binding and gene expression
data (Figure 2) suggested that these compounds were partial
agonists. In contrast, the competitive binding and inhibition of
TCDD-inducible gene expression observed with PPD and PPT
would suggest that they functioned as AHR antagonists. Interest-
ingly, Re appeared to be a unique nonproductive AHR ligand for
guinea pig in that it could effectively compete for ligand binding
but not significantly stimulate or inhibit AHR-dependent gene
expression, but it could induce AHR-dependent luciferase
expression in rat cells (Table 3).
Endogenous Gene Cyp1a1 Expression
To confirm the ability of ginsenosides to induce expression of an
endogenous AhR-responsive gene, in addition to the stably
transfected DRE-luciferase reporter, we examined its effect on
CYP1A1 expression (i.e., mRNA levels) using RT-PCR. Incuba-
tion of mouse hepatoma (hepa1c1c7) cells with ginsenosides (Rc,
Rh1, PPD, F11) for 4 h increased CYP1A1 mRNA levels, albeit to
a lower level than that induced by TCDD (Figure 4), but these
data were consistent with the reporter gene induction results and
the AhR agonist activity of these ginsenosides.
Molecular Docking on Homology Models
To analyze the molecular determinants of the observed ability
of several ginsenosides to compete with [3H]TCDD for binding to
the gpAHR, PPD and PPT binding were computationally
simulated. To this end, a homology model of the gpAHR LBD
was developed using the procedure we previously described for
other AHR LBDs [22], and ensemble docking calculations were
performed for these ligands and TCDD (see Methods section for
the details). The use of a homology model in lieu of an available
experimental structure, along with the limitations of current
docking methods in including protein flexibility during docking
[34], prevented the use of the above computational protocol for
modeling the binding of ginsenosides with larger molecular
structures than PPD/PPT to the AhR.
Docking calculations predicted a binding pose for the TCDD in
the middle of the gpAHR binding cavity (see Figure 5A). Since this
cavity shares similar structural characteristics and conserved
internal residues with other mammalian AHRs with high TCDD
affinity [35], the binding geometry was very similar to those
predicted for mAHR and rtAHR [22]. Moreover, the
TCDD:gpAHR complex was stabilized by the same interactions
previously predicted and validated by mutagenesis experiments of
the TCDD:mAHR complex [36,37,22].
Stable docking poses were obtained also for PPD and PPT
within the binding cavity, with very similar placements (see
Figure 5A). The interactions that mainly stabilized binding of these
ginsenosides (Figure 5B) involved the central polar residues H290
and Q382, which interacted with the central hydroxyl groups of
the ligands, as well as several hydrophobic residues at the entrance
of the cavity (F294, M339 and M347) and lining the inner part of
the cavity (F286, L307, L314 and L352). Some of these
interactions were the same as those observed for TCDD.
However, one difference was that TCDD is a relatively small
molecule (228 A˚3 volume), compared to PPD and PPT (389 A˚3
and 390 A˚3 volume, respectively) and in contrast to TCDD, the
larger PPD and PPT molecules completely occupied the free
internal space available in the LBD.
A confirmation of this precise fit between the ligand structures
and the binding cavity features was supported by the results
obtained by docking PPD and PPT to the mAHR, rtAHR and
huAHR LBD models (data not shown). While docking poses
similar to that described for gpAHR were obtained in the mAHR
and rtAHR models, which share the same cavity features, no
docking poses were obtained in the huAHR. There was a unique
residue within the binding cavity of the huAHR (val381) that is
different from that in the analogous position of the C57BL/6
mouse AHR LBD (ala375), and the lower affinity of TCDD for
Table 2. Competitive binding of ginsenosides to the guinea pig hepatic cytosolic AHR.
Competitor Concentration (mM) [3H]-TCDD Specific Binding (Percent of Displacement)a
Rg1 200 6.167.6
Rb1 200 14.767.4
Rg2 200 21.268.3b
Rd 200 22.366.2b
Rb2 200 23.5617.4
Rb3 200 23.7614.7
F11 200 28.069.1b
TG 200 31.061.5b
Re 200 38.6612.0b
PPD 200 45.563.7b
Rh1 200 45.9623.2b
PPT 200 48.163.5b
Rh2 200 50.964.4b
Rc 200 88.263.9b
Guinea pig hepatic cytosol was incubated with 2 nM [3H]-TCDD in the absence or presence of 200 nM TCDF or the indicated ginsenoside for 2 hours at 20uC and [3H]-
TCDD specific binding was determined using the hydroxyapatite binding assay as described in the Materials and Methods section. a Values were expressed as a percent
of the total [3H]-TCDD specific binding and represented the mean6 SD of triplicate determinations. b Values represented that the amount of [3H]-TCDD specific binding
was significantly displaced by the competitors at p,0.05 (*) as determined by Student’s t-test.
doi:10.1371/journal.pone.0066258.t002
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huAHR was attributed to the steric hindrance imparted by this
residue that reduces the cavity space available, and affects TCDD
placement and interactions [22,35]. From our calculations, the
presence of this residue in the modeled huAHR LBD, along with
slight conformational differences of some hydrophobic residues in
the inner part of the cavity, were sufficient to prevent PPD and
PPT binding, although whether they actually interact with the
huAHR remains to be determined. Finally, the ability of PPD and
PPT to completely fill the available space in the gpAHR cavity (as
well as in the mAHR and rtAHR cavities) could result in a severe
reduction in the flexibility of the domain and a consequential
inhibition of the conformational changes associated with ligand
activation of AHR. This observation would be more consistent
with the activity of PPD and PPT as TCDD antagonists than
AHR agonists, which awaits experimental confirmation.
Species Specificity Of Ginsenosides As Ahr Agonists In
Rat, Mouse and Human Cell Lines
Dramatic species differences in the ability of chemicals to bind
to and activate/inhibit the AHR have been previously reported
[21,38]. The above results indicate the ability of various ginseno-
sides to bind to and activate the gpAHR. Docking analysis indicate
the ability of at least PPT and PPD to interact with the receptors
from various species (although docking results with the huAHR
could not be determined). Accordingly, to examine the species
specificity of ginsenosides as AHR agonists, we evaluated their
ability to induce DRE-luciferase gene expression in stably
transfected rat (H4L1.1c4), mouse (H1L1.1c2) and human
(HG2L6.1c3) hepatoma cell lines. Similar to the results obtained
with guinea pig cells, most ginsenosides were inactive as AHR
agonists. Rc is the only ginsenoside that consistently induced gene
expression in guinea pig, rat and mouse cell lines (Figure 3 &
Table 3). Rb3, Rc, Rh1, Rh2, F11 and TG induced gene
expression in guinea pig cells; Rb3, Rc, Re, Rg1 and F11 induced
gene expression in rat cells; Rc, Rg1 and PPT induced gene
expression in mouse cells; Rb2, Rc and Rh2 induced gene
expression in human cells.
Table 3. Ginsenoside agonist activity in AHR-responsive recombinant guinea pig (G16L1.1c8), rat (H4L1.1c4), mouse (H1L1.1c2)
and human (HG2L6.1c3) cells.
Treatment Luciferase Activity in Different Cell Lines (Percent of TCDD)
a
Chemical Concentration G16L1.1c8 H4L1.1c4 H1L1.1c2 HG2L6.1c3
TCDD 1 nM 100612 100611 100616 10063
Rb1 10 mM 162 2160 2161 362
Rb2 10 mM 161 2261 2260 1964
b
Rb3 10 mM 762
b 1363b 561l 562
Rc 10 mM 2466b 2366b 1763b 1962b
Rd 10 mM 264 060 2261 561
Re 10 mM 063 38613b 462 161
Rg1 10 mM 062 1260
b 1063b 161
Rg2 10 mM 061 261 562 260
Rh1 10 mM 2762
b 564 262 660
Rh2 10 mM 2964
b 061 364 862b
PPD 10 mM 062 2361 462 562
PPT 10 mM 462 663 761b 661
F11 10 mM 1263b 862b 364 661
TG 10 mM 2863b 362 263 762b
Cells were incubated with 10 mM of indicated ginsenoside for 4 hours and luciferase activity was determined as described in Materials and Methods section. a Values
were expressed as the percentage of 1 nM TCDD induction and represented the mean 6 SD of triplicate determinations. b Values were significantly different from the
DMSO-treated sample at p,0.05 as determined by Student’s t-test.
doi:10.1371/journal.pone.0066258.t003
Figure 4. Endogenous gene CYP1A1 expression in mouse
hepatoma cells. Hepa1c1c7 cells were incubated with DMSO (1%,
final concentration), TCDD (1 nM), or ginsenosides (10 mM) for 4 h at
37uC, mRNA was extracted, subjected to RT-PCR and amplification. The
asterisk indicated that the gene expression was significantly induced
compared to DMSO-treated sample at p,0.05 (*).
doi:10.1371/journal.pone.0066258.g004
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Dose-Dependent Induction Luciferase Activity of Rc In
Different Cell Lines
Considering that Rc was the most efficacious ligand in the DNA
and ligand binding assays, we chose Rc to examine the ability of
different concentrations to induce luciferase reporter gene activity
in cell lines from different species. Dose-dependent induction of
luciferase by RC at 4 h was observed to levels greater than 75% of
that induced by 1 nM TCDD in guinea pig, rat, mouse and
human cell lines (Figure 6). The EC50 values of luciferase
induction by Rc in G16L1.1c8, H4L1.1c4, H1L1.1c2 and
HG2L6.1c3 cells were 11.5 mM, 100 mM, 127 mM and
13.3 mM, respectively. These results indicated that Rc was a
relatively weak AHR agonist when compared to TCDD and other
potent HAH and PAH ligands in these cell lines. Taken together,
our results demonstrate the ability of selected ginsenosides to
stimulate and/or inhibit the functionality of the AHR and AHR-
dependent gene expression, with some compounds exhibiting
species- and/or cell-specific differences in AHR responsiveness.
Thus, ginsenosides represent a new class of naturally-occurring
AHR ligands with compound selective agonist, antagonist or
nonproductive ligand effects.
Discussion
The AHR is a transcription factor that responds to structurally
diverse ligands, and the activation of the AHR signal transduction
pathway not only produces a spectrum of ligand-, species- and
tissue-specific toxic and biological responses, but also plays a
critical role in immune function, cardiovascular physiology and
other endogenous functions [1–3]. Although TCDD and related
toxic environmental contaminants have been extensively charac-
terized as AHR ligands, an increasing number of reports have
demonstrated the ability of a variety of endogenous chemicals and
naturally occurring dietary compounds to interact with and
activate the AHR and AHR signaling pathway. For example,
numerous dietary phytochemicals have been shown to bind and/
or modulate AHR action, and these include diindolylmethane,
indole-3-carbinol (I3C) and its acidic condensation product indolo-
[3,2b]carbazole, and various flavonoids, carotenoids and other
chemicals [39–42]. In fact, recent studies have reported the ability
of dietary AHR active compounds present in cruciferous
vegetables to promote intestinal immune function, revealing the
AHR as a critical link between diet and immunity [43,44].
Here, we have demonstrated for the first time the ability of
several naturally-occurring ginsenosides to directly bind to and
activate/inhibit the AHR and AHR signal transduction pathway.
Interestingly, our results indicate a divergence in response for these
compounds, with several ginsenosides (e.g. Rc and Rh1) exhibiting
pure AHR agonist activity, albeit as relatively weak agonists, while
other compounds (e.g. Rh2, PPD and PPT) exhibited AHR
antagonist activity, in that they could directly bind to the AHR, yet
inhibited TCDD-dependent induction of AHR-responsive lucif-
erase gene expression. In contrast, other ginsenosides like F11, the
unique component found in American but not Asian ginseng
species, exhibited novel AHR activity in that it could exert both
agonist and antagonist activity at the same concentration. F11
could competitively bind to the AHR, stimulate AHR transfor-
mation, and DNA binding (agonist activity), but it also could
inhibit TCDD induced AHR-dependent luciferase reporter gene
expression (antagonist activity). While the mechanism of this novel
action remains to be determined, this differential response could
contribute to some of the differences in the biological and
physiologic effects produced by American versus Asian ginseng
species.
Comparison of the ability of each ginsenoside to induce AHR-
dependent luciferase gene expression in cell lines from different
species has revealed some interesting similarities and differences in
species-specificity in response to these compounds. The ability of
Rc to induce AHR-dependent gene expression to a comparable
level in guinea pig, mouse, rat and human cell lines indicated that
Rc was an AHR agonist of comparable potency/efficacy in each of
these species. In contrast, comparison of luciferase gene induction
in guinea pig, mouse, rat and human cells by all ginsenosides
revealed numerous other ginsenosides exhibited species-/cell-
Figure 5. Ligand docking to the gpAHR LBD homology model. (A) Superimposition of the docking poses of PPT, PPD and TCDD (green, blue,
and dark-gray sticks, respectively) in the gpAHR LBD model (cartoons). (B) PPT docking pose (green sticks) in the gpAHR LBD model (cartoons) with
the most interesting interacting residues highlighted (light-gray sticks and van der Waals surfaces).
doi:10.1371/journal.pone.0066258.g005
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specific differences in AHR agonist activity (Table 3). For
example, ginsenoside Re induced luciferase to 38% of that of
TCDD in rat H4L1.1c4 cells, yet little or no induction was
observed in mouse, guinea pig or human cells. Similarly, Rh1 and
TG induced luciferase activity in guinea pig cells to between 25–
30% of that induced by TCDD, yet little or no induction was
observed in other cells, while Rb2 could induce luciferase activity
only in human cells to 19%. Rc induced luciferase activity in all
the cell lines we used. While differences in cellular metabolism
between these cell lines (i.e. differences in metabolic degradation of
these compounds in different cell lines) could contribute to these
species differences, species-specific differences in key amino acids
within the ligand binding pocket of the AHR could also contribute
to this differential response. In fact, comparison of the AHR ligand
binding domain from different species revealed significant
differences in amino acids within the ligand binding pocket
[35,37], and species-specific differences in AHR ligand binding
specificity have previously been reported by several laboratories
[10,11]. While molecular docking approaches provided one
avenue to examine specific interactions of ligands with amino
acids within the modeled ligand binding pocket of the AHR from
several species, current limitations as described above precluded
our specific binding analysis of the majority of the ginsenosides.
However, docking results with PPT and PPD not only revealed
similarities in the specific binding interactions of these compounds
within the gpAHR LBD, but also similarities in ligand binding
characteristics between species. Whether species-specific binding
interactions actually occur remains to be experimentally verified.
In addition to ligand binding, the reported ability of various
ginsenosides to affect cell signaling pathways and enzymes,
coupled with the documented ability of some cell signaling
pathways to affect AHR-dependent gene expression suggest that
species- and/or cell-specific differences in these or other targets
could contribute to the observed differences in AHR ligand
efficacy and response [3,45], although this remains to be
confirmed. Taken together, these results confirmed AHR agonist
activity of several ginsenosides in several species.
Comparing the relative activity of the ginsenosides in different
AHR-based assays, some discrepancies in activity were apparent.
For example, differences in the relatively efficacy/activity of Rc
were observed in the guinea pig AHR bioassays. While Rc could
stimulate AHR transformation and DNA binding to a level
comparable to that of a maximal activating concentration of
TCDD (Figure 3), AHR-dependent reporter gene activity was
stimulated to only ,24% of that of TCDD in the guinea pig cell
line (Figure 2). Similar differences in AHR ligand efficacy/potency
Figure 6. Dose-dependent induction of luciferase activity by TCDD and Rc in AHR-responsive recombinant guinea pig (G16L1.1c8),
rat (H4L1.1c4), mouse (H1L1.1c2) and human (HG2L6.1c3) cells. Cells were incubated with the indicated concentration of Rc for 4 h and
luciferase activity was determined as described in Materials and Methods section. Dose-dependent induction of luciferase activity by TCDD and Rc in
(A) G16L1.1c8, (B) H4L1.1c4, (C) H1L1.1c2 and (D) HG2L6.1c3 cells were shown. Values were expressed in the figure as the percentage of maximal
TCDD induction and represented the mean 6 SD of triplicate determinations. All concentrations of TCDD $10211 M and of Rc $1025 M were
significantly greater than DMSO-treated sample at p,0.01 as determined by Student’s t-test.
doi:10.1371/journal.pone.0066258.g006
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between in vitro and cell-based AHR assays have been previously
observed and primarily resulted from the greater efficiency of a
ligand to activate the cytosolic AHR in vitro, since the ligand has
direct access to the AHR with little degrading enzymes present
[46,47]. A comparable response in intact cells would require all of
the added ligand to enter the cell (without loss to serum proteins),
it must avoid sequestration (by membranes, lipids, proteins, and
organelles) and metabolism (by enzymes such as cytochrome
P450s), and must find and bind to the AHR, fully stimulating
AHR nuclear localization, transformation and DNA binding, and
induction of gene expression, all within the time frame of the
bioassays. Considering that ginsenosides appear to be highly
susceptible to metabolism, significant reductions in their inducing
potency in cell based assays are expected.
Major biological effects of ginsenosides include the enhance-
ment of cholesterol biosynthesis [48], immunomodulatory and
anti-inflammatory activity [49], antidiabetic and antioxidant
effects [50,51], cardiovascular protection [52], chemotherapeutic
activities and neuroprotective effects [52,53]. To date, more than
30 ginsenosides have been found in extracts of P. ginseng, with
more than 60 isolated from members of the Panax genus, these
include the oleanolic acid type ginsenosides (including R0), the 20
(S)-protopanaxadiol (PPD) type ginsenosides (including Ra, Rb,
Rc, Rd, Rg3, Rh2 and Rs) and the 20 (S)-protopanaxatriol (PPT)
type ginsenosides (including Re, Rf, Rg1, Rg2 and Rh1). While
many of these compounds have shown to contribute to the wide
range of medicinal effects of ginseng, it is likely that many distinct
mechanisms of action (biological and toxic) exist for these different
compounds, of which activation/inhibition of the AHR signaling
pathway is only one. Considering the currently large consumption
of ginseng and the diversity in effects, it is suggested that more
extensive studies should be conducted on the biological and
physiologic effects and mechanism of ginsenosides. Whether
ginsenosides exert some of their beneficial clinical effects through
an AHR-dependent pathway, and how exactly these structurally
unique chemicals can bind within the AHR ligand binding pocket
and activate/inhibit the AHR are exciting areas for future
research.
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